-
Je něco špatně v tomto záznamu ?
Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation
S. Koudelka, J. Mašek, J. Neužil, J. Turánek
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Medline Complete (EBSCOhost)
od 2005-06-01 do 2015-12-31
Wiley Online Library (archiv)
od 1996-01-01 do 2012-12-31
PubMed
20039382
DOI
10.1002/jps.22002
Knihovny.cz E-zdroje
- MeSH
- alfa-tokoferol aplikace a dávkování chemie MeSH
- lipidy chemie MeSH
- liposomy MeSH
- lyofilizace MeSH
- lysofosfolipidy chemie MeSH
- peroxid vodíku chemie MeSH
- povrchové vlastnosti MeSH
- příprava léků metody MeSH
- protinádorové látky aplikace a dávkování chemie MeSH
- skladování léků MeSH
- stabilita léku MeSH
- transmisní elektronová mikroskopie MeSH
- velikost částic MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
alpha-Tocopheryl succinate (alpha-TOS) is a semisynthetic analogue of alpha-tocopherol with selective toxicity to the cancer cells and anticancer activity in vivo. Yet, no suitable formulation of alpha-TOS for medical application has been reported. Various formulations, for example, solutions in organic solvents, oil emulsions and vesicules prepared by spontaneous vesiculation, polyethylene glycol conjugates and liposomes of various compositions have been tested. We developed and characterised a stable lyophilised liposome-based alpha-TOS formulation. alpha-TOS (15 mol%) was incorporated into large oligolamellar vesicles (OLVs) composed of soy phosphatidylcholine (SPC) by the method of lipid film hydration followed by extrusion through polycarbonate filters. Stabilised liposomal formulation was prepared by lyophilisation in the presence of sucrose (molar ratio lipid/sucrose, 1:5). The size distribution of the liposomes (130-140 nm, polydispersity index 0.14) as well as the stable lipid and alpha-TOS contents were preserved during storage in the lyophilised form at 2-8 degrees C for at least 6 months. The data indicate good physical and chemical stability of the lyophilised preparation of alpha-TOS liposomes that can be used in clinical medicine.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025334
- 003
- CZ-PrNML
- 005
- 20130206152042.0
- 007
- ta
- 008
- 120816s2010 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1002/jps.22002 $2 doi
- 035 __
- $a (PubMed)20039382
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Koudelka, Štěpán $7 xx0137876 $u Department of Vaccinology and Immunotherapy, Veterinary Research Institute, Hudcova 70, 62132 Brno, Czech Republic
- 245 10
- $a Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation / $c S. Koudelka, J. Mašek, J. Neužil, J. Turánek
- 520 9_
- $a alpha-Tocopheryl succinate (alpha-TOS) is a semisynthetic analogue of alpha-tocopherol with selective toxicity to the cancer cells and anticancer activity in vivo. Yet, no suitable formulation of alpha-TOS for medical application has been reported. Various formulations, for example, solutions in organic solvents, oil emulsions and vesicules prepared by spontaneous vesiculation, polyethylene glycol conjugates and liposomes of various compositions have been tested. We developed and characterised a stable lyophilised liposome-based alpha-TOS formulation. alpha-TOS (15 mol%) was incorporated into large oligolamellar vesicles (OLVs) composed of soy phosphatidylcholine (SPC) by the method of lipid film hydration followed by extrusion through polycarbonate filters. Stabilised liposomal formulation was prepared by lyophilisation in the presence of sucrose (molar ratio lipid/sucrose, 1:5). The size distribution of the liposomes (130-140 nm, polydispersity index 0.14) as well as the stable lipid and alpha-TOS contents were preserved during storage in the lyophilised form at 2-8 degrees C for at least 6 months. The data indicate good physical and chemical stability of the lyophilised preparation of alpha-TOS liposomes that can be used in clinical medicine.
- 650 _2
- $a protinádorové látky $x aplikace a dávkování $x chemie $7 D000970
- 650 _2
- $a příprava léků $x metody $7 D004339
- 650 _2
- $a stabilita léku $7 D004355
- 650 _2
- $a skladování léků $7 D004356
- 650 _2
- $a lyofilizace $7 D005612
- 650 _2
- $a peroxid vodíku $x chemie $7 D006861
- 650 _2
- $a lipidy $x chemie $7 D008055
- 650 _2
- $a liposomy $7 D008081
- 650 _2
- $a lysofosfolipidy $x chemie $7 D008246
- 650 _2
- $a transmisní elektronová mikroskopie $7 D046529
- 650 _2
- $a velikost částic $7 D010316
- 650 _2
- $a povrchové vlastnosti $7 D013499
- 650 _2
- $a alfa-tokoferol $x aplikace a dávkování $x chemie $7 D024502
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mašek, Josef $7 xx0171644
- 700 1_
- $a Neužil, Jiří, $d 1958- $7 xx0115772
- 700 1_
- $a Turánek, Jaroslav $7 xx0118573
- 773 0_
- $w MED00002895 $t Journal of pharmaceutical sciences $x 1520-6017 $g Roč. 99, č. 5 (2010), s. 2434-2443
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20039382 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20130206152217 $b ABA008
- 999 __
- $a ok $b bmc $g 947376 $s 782680
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 99 $c 5 $d 2434-2443 $i 1520-6017 $m Journal of pharmaceutical sciences $n J Pharm Sci $x MED00002895
- LZP __
- $a Pubmed-20120816/10/02